Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117489 | 0.85 | KMT2A (0.60) | TSHRMEN1CYP2D6KMT2AHRH2 | |
| SCHEMBL9431699 | 0.83 | TP53 (0.55) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL9942262 | 0.82 | TP53 (0.55) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL12736505 | 0.81 | TSHR (0.54) | TSHRMEN1CYP2D6KMT2A | |
| SCHEMBL20021242 | 0.81 | HPGD (0.63) | TP53TSHRHRH2HRH1 | |
| SCHEMBL30949365 | 0.80 | HRH3 (0.59) | HRH2HRH1 | |
| SCHEMBL15382224 | 0.79 | RARB (0.57) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL12420679 | 0.78 | NFE2L2 (0.52) | MEN1CYP2D6KMT2AHRH2HRH1 | |
| SCHEMBL11701844 | 0.77 | HRH2 (0.58) | MEN1CYP2D6KMT2AHRH2HRH1 | |
| SCHEMBL230405 | 0.77 | NPC1 (0.71) | TSHRMEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | TP53 4609/4885TSHR 4221/4885PLA2G4B 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.